We don't know whether the most recent response to this request contains information or not – if you are Ed Fryer please sign in and let everyone know.

Brain Cancer Treatment

We're waiting for Ed Fryer to read recent responses and update the status.

Dear Lancashire Teaching Hospitals NHS Foundation Trust,

I'd like to please request the following information.

1. How many patients have been treated for glioblastoma brain cancer in the last 12 months, in your trust/ health board?

2. Which consultant is the nominated medical lead for the treatment or referral of glioblastoma brain cancer?

3.Does your trust/ health board treat all referred glioblastoma brain cancer cases, or are they referred to different centre's? If so, which treatment centre(s) are they referred to?

Thank you for answering these questions.

Yours faithfully,
Ed Fryer

Freedom of Information (LTHTR), Lancashire Teaching Hospitals NHS Foundation Trust

Dear Ed Fryer,

What organisation is this request being submitted by/on behalf of? This information is required under section 12.

Regards,

Freedom of Information Officer

Technology Services | Lancashire Teaching Hospitals NHS Foundation Trust | Royal Preston Hospital | Sharoe Green Lane | Preston | Lancashire | PR2 9HT
Email: [Lancashire Teaching Hospitals NHS Foundation Trust request email] | Website: www.lancsteachinghospitals.nhs.uk

show quoted sections

Freedom of Information (LTHTR), Lancashire Teaching Hospitals NHS Foundation Trust

See response below.

FOI Request 8644

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for the following conditions?

* Cervical cancer
* Endometrial cancer

Trust response: Yes

In case you do not provide SACT treatments for either of the above conditions, which other trust do you refer patients to for these treatments?

Q2. How many patients were treated for cervical cancer in the past 6 months with the following treatments:

Trust response:

Paclitaxel in combination with Platinum and/or Bevacizumab 1
Pembrolizumab in combination with Platinum and/or Bevacizumab 0
Platinum standalone or in combination with Bevacizumab 20
Toptecan in combination with Platinum and/or Bevacizumab 0
Any other SACT 1

Q3. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:

Trust response:

Dostarlimab 1
Hormone therapy (Progesterone or Letrozole) Information not recorded
Pembrolizumab in combination with Lenvatinib 0
Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) 7
Any other SACT 8

Q4. How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:

* Hormone therapy (Progesterone or Letrozole)
* Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
* Any other SACT

Trust response: Information not recorded

Q5. Does your trust participate in any clinical trials for the treatment of cervical cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Trust response: No

Q6. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Trust response: No

Regards,

Freedom of Information Officer

Technology Services | Lancashire Teaching Hospitals NHS Foundation Trust | Royal Preston Hospital | Sharoe Green Lane | Preston | Lancashire | PR2 9HT
Email: [Lancashire Teaching Hospitals NHS Foundation Trust request email] | Website: www.lancsteachinghospitals.nhs.uk

show quoted sections

Dear Freedom of Information (LTHTR),

I hope this finds you well

APologies but i believe the response sent to me was for a different FOI response

Yours sincerely,

Ed Fryer

Freedom of Information (LTHTR), Lancashire Teaching Hospitals NHS Foundation Trust

Dear Ed Fryer

Please see below.

FOI Request 8645

1. How many patients have been treated for glioblastoma brain cancer in the last 12 months, in your trust/ health board?

Trust response: 54

2. Which consultant is the nominated medical lead for the treatment or referral of glioblastoma brain cancer?

Trust response: The MDT lead is a Consultant Neurosurgeon. The medical oncologist is a Consultant Clinical Oncologist

3.Does your trust/ health board treat all referred glioblastoma brain cancer cases, or are they referred to different centre's? If so, which treatment centre(s) are they referred to?

Trust response: All

Regards,

Freedom of Information Officer

Technology Services | Lancashire Teaching Hospitals NHS Foundation Trust | Royal Preston Hospital | Sharoe Green Lane | Preston | Lancashire | PR2 9HT
Email: [Lancashire Teaching Hospitals NHS Foundation Trust request email] | Website: www.lancsteachinghospitals.nhs.uk

show quoted sections

We don't know whether the most recent response to this request contains information or not – if you are Ed Fryer please sign in and let everyone know.